Imaging approaches for dementia

American Journal of Neuroradiology

Volumn 33, Issue 10, 2012, Pages 1836-1844

  Murray, Allison D ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IOMETOPANE I 123;

ALZHEIMER DISEASE; CARDIOVASCULAR DISEASE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; FRONTOTEMPORAL DEMENTIA; MOLECULAR IMAGING; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BRAIN; DEMENTIA; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; WHOLE BODY IMAGING;

EID: 84870953950     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A2782     Document Type: Review

References (83)

1. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol 2011;7:137-52
2. Matthews FE, Brayne C, Lowe J, et al. Epidemiological pathology of dementia: attributable-risks at death in the medical research council cognitive function and ageing study. PLoS Med 2009;6:e1000180
3. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2001;56:1143-53 (Pubitemid 32405708)
4. Matsuda H. Role of neuroimaging in Alzheimer's disease, with emphasis on brain perfusion SPECT. J Nucl Med 2007;48:1289-300. Epub 2007 Jul 13
5. Jack CR Jr, Bernstein MA, Borowski BJ, et al. Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. Alzheimers Dement 2010;6:212-20
6. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-46 (Pubitemid 47058377)
7. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-69
8. Alzheimer A, Stelzmann RA, Schnitzlein HN, et al. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde."Clin Anat 1995;8:429-31
9. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59
10. Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008;9:768-78
11. Li YJ, Hauser MA, Scott WK, et al. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology 2004;62:2005-09 (Pubitemid 38738212)
12. Jack CR Jr, Dickson DW, Parisi JE, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002;58:750-57 (Pubitemid 34211554)
13. Ikram MA, Vrooman HA, Vernooij MW, et al. Brain tissue volumes in relation to cognitive function and risk of dementia. Neurobiol Aging 2010;31:378-86
14. Jack CR Jr, Shiung MM, Gunter JL, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004;62:591-600 (Pubitemid 38252801)
15. Barnes J, Bartlett JW, van de Pol LA, et al. A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol Aging 2009;30:1711-23
16. Staff RT, Murray AD, Ahearn T, et al. Brain volume and survival from age 78 to 85: the contribution of Alzheimer-type magnetic resonance imaging findings. J Am Geriatr Soc 2010;58:688-95
17. Pruessner JC, Li LM, Serles W, et al. Volumetry of hippocampus and amygdala with high-resolution MRI and three-dimensional analysis software: minimizing the discrepancies between laboratories. Cereb Cortex 2000;10:433-42 (Pubitemid 30185342)
18. Langbaum JB, Chen K, Lee W, et al. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage 2009;45:1107-16
19. Wyper D, Teasdale E, Patterson J, et al. Abnormalities in rCBF and computed tomography in patients with Alzheimer's disease and in controls. Br J Radiol 1993;66:23-27 (Pubitemid 23049577)
20. Samuraki M, Matsunari I, Chen WP, et al. Partial volume effect-corrected FDG PET and grey matter volume loss in patients with mild Alzheimer's disease. Eur J Nucl Med Mol Imaging 2007;34:1658-69 (Pubitemid 47476921)
21. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-28
22. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004;55:306-19 (Pubitemid 38269583)
23. Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 2010;51:913-20
24. Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010;68:319-29
25. Jack CR Jr, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010;133:3336-48
26. Rabinovici GD, Furst AJ, Alkalay A, et al. Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain 2010;133:512-28
27. Kadir A, Marutle A, Gonzalez D, et al. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh compound B positron emission tomography patient with Alzheimer's disease. Brain 2011;134:301-17
28. Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol 2009;21:117-28
29. Apostolova LG, Thompson PM, Green AE, et al. 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. Hum Brain Mapp 2010;31:786-97
30. Leow AD, Yanovsky I, Parikshak N, et al. Alzheimer's Disease Neuroimaging Initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage 2009;45:645-55
31. Walhovd KB, Fjell AM, Brewer J, et al. Combining MR imaging, positronemission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am J Neuroradiol 2010;31:347-54
32. Strozyk D, Dickson DW, Lipton RB, et al. Contribution of vascular pathology to the clinical expression of dementia. Neurobiol Aging 2010;31:1710-20
33. Fazekas F, Chawluk JB, Alavi A, et al. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987;149:351-56 (Pubitemid 17104996)
34. Scheltens P, Barkhof F, Leys D, et al. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 1993;114:7-12 (Pubitemid 23025201)
35. de Boer R, Vrooman HA, van der Lijn F, et al. White matter lesion extension to automatic brain tissue segmentation on MRI. Neuroimage 2009;45:1151-61
36. Murray AD, Staff RT, Shenkin SD, et al. Brain white matter hyperintensities: relative importance of vascular risk factors in nondemented elderly people. Radiology 2005;237:251-57 (Pubitemid 41346171)
37. Murray AD, Staff RT, McNeil CJ, et al. Brain lesions, hypertension and cognitive ageing in the 1921 and 1936 Aberdeen birth cohorts. Age (Dordr) 2012;34:451-59
38. Leaper SA, Murray AD, Lemmon HA, et al. Neuropsychologic correlates of brain white matter lesions depicted on MR images: 1921 Aberdeen birth cohort. Radiology 2001;221:51-55 (Pubitemid 32880370)
39. Gunning-Dixon FM, Raz N. The cognitive correlates of white matter abnormalities in normal aging: a quantitative review. Neuropsychology 2000;14:224-32
40. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010;341:c3666
41. Kearney-Schwartz A, Rossignol P, Bracard S, et al. Vascular structure and function is correlated to cognitive performance and white matter hyperintensities in older hypertensive patients with subjective memory complaints. Stroke 2009;40:1229-36
42. Raz N, Rodrigue KM, Kennedy KM, et al. Vascular health and longitudinal changes in brain and cognition in middle-aged and older adults. Neuropsychology 2007;21:149-57 (Pubitemid 46631097)
43. Fischer P, Krampla W, Mostafaie N, et al. VITA study: white matter hyperintensities of vascular and degenerative origin in the elderly. J Neural Transm Suppl 2007:181-88
44. Jagust WJ, Zheng L, Harvey DJ, et al. Neuropathological basis of magnetic resonance images in aging and dementia. Ann Neurol 2008;63:72-80 (Pubitemid 351240553)
45. Doubal FN, MacLullich AM, Ferguson KJ, et al. Enlarged perivascular spaces on MRI are a feature of cerebral small vessel disease. Stroke 2010;41:450-54
46. Vernooij MW, de Groot M, van der Lugt A, et al. White matter atrophy and lesion formation explain the loss of structural integrity of white matter in aging. Neuroimage 2008;43:470-77
47. Poels MM, Vernooij MW, Ikram MA, et al. Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam scan study. Stroke 2010;41(10 suppl):S103-06
48. Brickman AM, Muraskin J, Zimmerman ME. Structural neuroimaging in Alzheimer's disease: do white matter hyperintensities matter? Dialogues Clin Neurosci 2009;11:181-90
49. Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 2010;119:1-4
50. Seeley WW, Crawford RK, Zhou J, et al. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009;62:42-52
51. Rabinovici GD, Seeley WW, Kim EJ, et al. Distinct MRI atrophy patterns in autopsy-proven Alzheimer's disease and frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen 2007;22:474-88
52. Panegyres PK, Rogers JM, McCarthy M, et al. Fluorodeoxyglucose-positron emission tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study. BMC Neurol 2009;9:41
53. Davatzikos C, Resnick SM, Wu X, et al. Individual patient diagnosis of AD and FTD via high-dimensional pattern classification of MRI. Neuroimage 2008;41:1220-27
54. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005;65:1863-72 (Pubitemid 43970103)
55. Zaccai J, Brayne C, McKeith I, et al. Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology 2008;70:1042-48 (Pubitemid 351451312)
56. Leverenz JB, Quinn JF, Zabetian C, et al. Cognitive impairment and dementia in patients with Parkinson disease. Curr Top Med Chem 2009;9:903-12
57. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68:1718-25 (Pubitemid 46763260)
58. Gomperts SN, Rentz DM, Moran E, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008;71:903-10
59. Ishii K, Imamura T, Sasaki M, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. Neurology 1998;51:125-30 (Pubitemid 28345371)
60. Teune LK, Bartels AL, de Jong BM, et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord 2010;25:2395-404
61. Ishii K, Soma T, Kono AK, et al. Comparison of regional brain volume and glucose metabolism between patients with mild dementia with Lewy bodies and those with mild Alzheimer's disease. J Nucl Med 2007;48:704-11 (Pubitemid 47604969)
62. Booij J, Speelman JD, Horstink MW, et al. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001;28:266-72
63. Staff RT, Ahearn TS, Wilson K, et al. Shape analysis of 123I-N-omega-fluoropropyl-2-beta-carbomethoxy-3beta-(4-iodophenyl) nortropane single-photon emission computed tomography images in the assessment of patients with parkinsonian syndromes. Nucl Med Commun 2009;30:194-201
64. Eshuis SA, Jager PL, Maguire RP, et al. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls. Eur J Nucl Med Mol Imaging 2009;36:454-62. Epub 2008 Nov 27
65. Walker Z, Jaros E, Walker RW, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 2007;78:1176-81 (Pubitemid 350057277)
66. Orimo S, Amino T, Itoh Y, et al. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 2005;109:583-88 (Pubitemid 40974147)
67. Cousins DA, Burton EJ, Burn D, et al. Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer's disease: an MRI study. Neurology 2003;61:1191-95 (Pubitemid 37377536)
68. Breen DP, Rowe JB, Barker RA. Role of brain imaging in early parkinsonism. BMJ 2011;342:d638
69. Rossor MN, Fox NC, Mummery CJ, et al. The diagnosis of young-onset dementia. Lancet Neurol 2010;9:793-806
70. Flanagan EP, McKeon A, Lennon VA, et al. Autoimmune dementia: clinical course and predictors of immunotherapy response. 2010;85:881-97
71. Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011;18:19-e3. Epub 2010 Sep 29
72. Josephs KA, Whitwell JL, Knopman DS, et al. Two distinct subtypes of right temporal variant frontotemporal dementia. Neurology 2009;73:1443-50
73. Heath CA, Cooper SA, Murray K, et al. Validation of diagnostic criteria for variant Creutzfeldt-Jakob disease. Ann Neurol 2010;67:761-70
74. Wu HM, Lu CS, Huang CC, et al. Asymmetric involvement in sporadic Creutzfeldt-Jakob disease: clinical, brain imaging, and electroencephalographic studies. Eur Neurol 2010;64:74-79
75. Collie DA, Summers DM, Sellar RJ, et al. Diagnosing variant Creutzfeldt-Jakob disease with the pulvinar sign: MR imaging findings in 86 neuropathologically confirmed cases. AJNR Am J Neuroradiol 2003;24:1560-69 (Pubitemid 37151720)
76. Kallenberg K, Schulz-Schaeffer WJ, Jastrow U, et al. Creutzfeldt-Jakob disease: comparative analysis of MR imaging sequences. AJNR Am J Neuroradiol 2006;27:1459-62 (Pubitemid 44260128)
77. Senocak E, Oguz KK, Ozgen B, et al. Imaging features of CNS involvement in AIDS. Diagn Interv Radiol 2010;16:193-200
78. Mohamed MA, Lentz MR, Lee V, et al. Factor analysis of proton MR spectroscopic imaging data in HIV infection: metabolite-derived factors help identify infection and dementia. Radiology 2010;254:577-86
79. Waiter GD, Fox HC, Murray AD, et al. Is retaining the youthful functional anatomy underlying speed of information processing a signature of successful cognitive ageing? An event-related fMRI study of inspection time performance. Neuroimage 2008;41:581-95
80. Mellon EA, Pilkinton DT, Clark CM, et al. Sodium MR imaging detection of mild Alzheimer disease: preliminary study. AJNR Am J Neuroradiol 2009;30:978-84
81. Staff RT, Murray AD, Deary IJ, et al. What provides cerebral reserve? Brain 2004;127:1191-99 (Pubitemid 38623052)
82. Wischik C, Staff R. Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of tau-aggregation inhibitor therapy. J Nutr Health Aging 2009;13:367-69
83. Filley CM, Anderson CA. Dementia: five new things. Neurology 2011;76:S26-30